• Clinical Trials - Congenital Myasthenic Sydromes (CMS)

    Study Objective Contact
    Open Label Trial Of 3,4-Diaminopyridine In Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS) [LCID Study Number: 2001-040] Purpose: This study is looking at the effectiveness and adverse effects of 3, 4 Diaminopyridine (3, 4 DAP) for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS). For more information on this study, please visit: http://www.lahey.org/Departments_and_Locations/Departments/Neurology/Research/Lambert_Eaton_Myasthenic_Syndrome_Trials.aspx Principal Investigator(s):
    Jayashri Srinivasan, MD, PhD, FRCP

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Sharmeen Alam, MHA.